4SC (immunology portfolio) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
4SC (immunology portfolio) General Information
Description
Immunology portfolio of 4SC. The portfolio consist of two Immunology drug development programs named IMU-366 and IMU-838 and associated intellectual property.
Contact Information
Corporate Office
- Martinsried
- Germany
Corporate Office
- Martinsried
- Germany
4SC (immunology portfolio) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
4SC (immunology portfolio) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
4SC (immunology portfolio) FAQs
-
Where is 4SC (immunology portfolio) headquartered?
4SC (immunology portfolio) is headquartered in Martinsried, Germany.
-
What industry is 4SC (immunology portfolio) in?
4SC (immunology portfolio)’s primary industry is Buildings and Property.
-
Is 4SC (immunology portfolio) a private or public company?
4SC (immunology portfolio) is a Private company.
-
What is 4SC (immunology portfolio)’s current revenue?
The current revenue for 4SC (immunology portfolio) is .
-
Who are 4SC (immunology portfolio)’s investors?
4SC has invested in 4SC (immunology portfolio).
-
When was 4SC (immunology portfolio) acquired?
4SC (immunology portfolio) was acquired on 28-Sep-2016.
-
Who acquired 4SC (immunology portfolio)?
4SC (immunology portfolio) was acquired by Immunic Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process